Incidence and burden of the myelodysplastic syndromes
CR Cogle - Current hematologic malignancy reports, 2015 - Springer
Since 2001, cases of myelodysplastic syndromes (MDSs) have been tracked by cancer
registries. Examining registry data in the USA, the reported age-adjusted incidence of MDS …
registries. Examining registry data in the USA, the reported age-adjusted incidence of MDS …
Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
AM Zeidan, T Salimi, RS Epstein - Future Oncology, 2021 - Taylor & Francis
Myelodysplastic syndromes are hematological malignancies characterized by ineffective
hematopoiesis and a high risk of progression to acute myeloid leukemia. Hypomethylating …
hematopoiesis and a high risk of progression to acute myeloid leukemia. Hypomethylating …
Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: a systematic literature review and meta‐analysis
M Braga Lemos, SR Rodrigues… - European Journal of …, 2021 - Wiley Online Library
Myelodysplastic syndromes (MDS) are a group of malignant hematologic diseases
characterized by ineffective hematopoiesis, which may lead to chronic anemia and …
characterized by ineffective hematopoiesis, which may lead to chronic anemia and …
[PDF][PDF] 骨髓增生异常综合征患者感染危险因素及预防
龚婧晔， 肖志坚 - 临床血液学杂志, 2021 - lcxyen.whuhzzs.com
Summary Myelodysplasticsyndromes (MDS) areaheterogeneousgroupofclonalmyeloidn…. PatientswithMDShavearelativelyhighriskofi…
-related, patient-relatedandtreatment-relatedfactors. Infectionremainsthemostimportantcauseofd …
-related, patient-relatedandtreatment-relatedfactors. Infectionremainsthemostimportantcauseofd …
Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations
The improvement in supportive care and the introduction of new therapeutic agents,
including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have …
including lenalidomide and hypomethylating agents, in myelodysplastic syndromes have …
Impact of frailty on health care resource utilization and costs of care in myelodysplastic syndromes
PURPOSE: The role of frailty in affecting survival in myelodysplastic syndromes (MDS) is
increasingly recognized. Despite this, a paucity of data exists on the association between …
increasingly recognized. Despite this, a paucity of data exists on the association between …
[HTML][HTML] Impact of lenalidomide treatment on overall survival in patients with lower-risk, transfusion-dependent myelodysplastic syndromes
V Santini, A Giagounidis, CG Pelligra… - … Myeloma and Leukemia, 2022 - Elsevier
MicroAbstract Overall survival (OS) is rarely a primary endpoint in lower-risk myelodysplastic
syndromes (LR-MDS) clinical trials. Predictors of OS were assessed in 592 patients from 3 …
syndromes (LR-MDS) clinical trials. Predictors of OS were assessed in 592 patients from 3 …
Red blood cell transfusion in myelodysplastic syndromes: A systematic review
S Kaka, A Jahangirnia, N Beauregard… - Transfusion …, 2022 - Wiley Online Library
Patients with myelodysplastic syndrome (MDS) frequently receive red blood cell (RBC)
transfusions for anaemia resulting from ineffective erythropoiesis. While RBC transfusions …
transfusions for anaemia resulting from ineffective erythropoiesis. While RBC transfusions …
Economic burden of patients treated for higher-risk myelodysplastic syndromes (HR-MDS) in routine clinical care in the United States
JA Bell, A Galaznik, M Blazer, HC Shih… - PharmacoEconomics …, 2019 - Springer
Abstract Background and Objective Significant clinical burden is associated with higher-risk
myelodysplastic syndromes (HR-MDS); however, the economic burden has not been fully …
myelodysplastic syndromes (HR-MDS); however, the economic burden has not been fully …
Physicians' experience in blood supply shortages and the top factors that impact the clinical, economic, and humanistic outcomes of patients with myelodysplastic …
S Gupta, AG Kulasekararaj, H Costantino… - Current Medical …, 2023 - Taylor & Francis
Objective Blood supply shortages may create unnecessary burden, including treatment
delay, worsened quality of life, or increased healthcare resource utilization in patients with …
delay, worsened quality of life, or increased healthcare resource utilization in patients with …